Moore Fabrice, Buonocore Sofia, Aksoy Ezra, Ouled-Haddou Najate, Goriely Stanislas, Lazarova Elena, Paulart Frédéric, Heirman Carlo, Vaeremans Elsy, Thielemans Kris, Goldman Michel, Flamand Véronique
Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
J Immunol. 2007 Feb 1;178(3):1301-11. doi: 10.4049/jimmunol.178.3.1301.
Maturation of dendritic cells (DC) is a critical step in the induction of T cell responses and depends on the activation of NF-kappaB transcription factors. Therefore, inhibition of NF-kappaB activation has been proposed as a strategy to maintain DC in an immature stage and to promote immune tolerance. Herein, we generated murine myeloid DC expressing a mutated IkappaBalpha acting as a superrepressor of the classical NF-kappaB pathway (s-rIkappaB DC) to investigate the consequences of NF-kappaB inhibition on the ability of DC to prime T cell responses. Upon in vitro LPS activation, maturation of s-rIkappaB DC was profoundly impaired as indicated by defective up-regulation of MHC class II and costimulatory molecules and reduced secretion of IL-12 p70 and TNF-alpha. In contrast, after injection, s-rIkappaB DC had the same capacity as control DC to migrate to draining lymph node and to induce Th1- and Th2-type cytokine production in a MHC class II-incompatible host mice. Likewise, s-rIkappaB DC pulsed with OVA were as efficient as control DC to induce Ag-specific T cell responses in vivo. Indeed, further in vitro experiments established that s-rIkappaB DC undergo efficient maturation upon prolonged contact with activated T cells via the alternative pathway of NF-kappaB activation triggered at least partly by lymphotoxin beta receptor ligation and involving processing of p100/RelB complexes.
树突状细胞(DC)的成熟是诱导T细胞应答的关键步骤,且依赖于核因子-κB转录因子的激活。因此,抑制核因子-κB激活已被提议作为一种将DC维持在未成熟阶段并促进免疫耐受的策略。在此,我们构建了表达一种突变型IκBα的小鼠髓样DC,该突变型IκBα作为经典核因子-κB途径的超级抑制剂(s-rIκB DC),以研究抑制核因子-κB对DC启动T细胞应答能力的影响。在体外脂多糖(LPS)激活后,s-rIκB DC的成熟受到严重损害,表现为MHC II类分子和共刺激分子上调缺陷,以及IL-12 p70和肿瘤坏死因子-α(TNF-α)分泌减少。相反,注射后,s-rIκB DC与对照DC具有相同的迁移至引流淋巴结的能力,并能在MHC II类不相容的宿主小鼠中诱导Th1型和Th2型细胞因子产生。同样,用卵清蛋白(OVA)脉冲处理的s-rIκB DC在体内诱导抗原特异性T细胞应答的效率与对照DC相同。事实上,进一步的体外实验证实,s-rIκB DC在通过至少部分由淋巴毒素β受体连接触发并涉及p100/RelB复合物加工的核因子-κB激活替代途径与活化T细胞长时间接触后,能够有效地成熟。